MedTrace Logo

Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients

NCT05755581 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-03-06

No results posted yet for this study

Summary

Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.

Conditions

  • Female Breast Cancer

Interventions

DRUG

Hormonal Antineoplastics

the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.

DRUG

Chemotherapy drug

the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Amal Ali, MD · Assistant lecturer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-04-01
Completion
2025-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05755581 on ClinicalTrials.gov